Membrane supported virus separation from biological solutions

Chemie-Ingenieur-Technik

Volumn 85, Issue 8, 2013, Pages 1183-1192

  Grein, Tanja A ^a,b   Kovacs, Zoltan ^a   Ebrahimi, Mehrdad ^a,b   Michalsky, Ronald ^c   Czermak, Peter ^a,d  

^a TECHNISCHE HOCHSCHULE MITTELHESSEN   (Germany)

^b EHC Memtec UG   (Germany)

^c Brown University   (United States)

^d Kansas State University   (United States)

Author keywords

Adsorptive membranes; Dead end filtration; Diafiltration; Gene therapy; Tangential flow filtration; Vaccine production; Virus clearance

Indexed keywords

ADSORPTIVE MEMBRANES; DEAD-END FILTRATION; DIAFILTRATION; TANGENTIAL FLOW FILTRATIONS; VACCINE PRODUCTION; VIRUS CLEARANCE;

CELL CULTURE; GENE THERAPY; MEMBRANES; VIRUSES;

MICROFILTRATION;

EID: 84880916601     PISSN: 0009286X     EISSN: 15222640     Source Type: Journal    
DOI: 10.1002/cite.201200241     Document Type: Review

References (97)

1. L. Pedro, S. S. Soares, G. N. M. Ferreira, Chem. Eng. Technol. 2008, 31 (6), 815-825. DOI: 10.1002/ceat.200800176
2. M. W. Wolf, U. Reichl, Expert Rev. Vaccines 2011, 10 (10), 1451-1475. DOI: 10.1586/erv.11.111
3. C. Justice, et al., Biotechnol. Adv. 2011, 29 (4), 391-401. DOI: 10.1016/j.biotechadv.2011.03.002
4. P. Czermak, D. Nehring, R. Wickramasinghe, in Membrane Filtration in Animal Cell Culture, Animal Cell Biotechnology: Methods and Protocols (Ed: R. Poertner), Humana Press, Totoba 2007, Ch. 19.
5. D. J. Betting, et al., Vaccine 2009, 27 (2), 250-259. DOI: 10.1016/j.vaccine.2008.10.055
6. K. Weiss, et al., Am. J. Biochem. Biotechnol. 2012, 8 (2), 81-98. DOI: 10.3844/ajbbsp.2012.81.98
7. L. J. Stanbridge, V. Dussupt, N. J. Maitland, J. Biomed. Biotechnol. 2003, 2003 (2), 79-91. DOI: 10.1155/S1110724303209049
8. Y. Hu, et al., J. Virol. 2001, 75 (21), 10300-10308.
9. H. Kamada, et al., Cancer Res. 2000, 60 (22), 6416-6420.
10. L. Shi, et al., J. Pharm. Sci. 2005, 94 (7), 1538-1551.
11. J. Lacroix, et al., Int. J. Cancer 2010, 127 (5), 1230-1239.
12. Note for Guideance on Plasma-Derived Medicinal Products, CPMP/BWP/269/95, rev. 3, European Agency for the Evaluation of Medicinal Products, London 2001.
13. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use, Food and Drug Administration, Rockville, MD 1997. www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/OtherRecommendationsforManufacturers/ UCM153182.pdf.
14. Q2(R1)Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonisation, Geneva 1996. www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Quality/Q2-R1/Step4/Q2-R1-Guideline.pdf.
15. Forty-seventh Report Technical Report Series, No 878, WHO Expert Committee on Biological Standardization, WHO, Geneva 1998.
16. WHO Technical Report Series No. 924, WHO, Geneva 2004.
17. A. Buchacher, G. Iberer, Biotechnol. J. 2006, 1 (2), 148-163. DOI: 10.1002/biot.200500037
18. U. Gottschalk, Process Scale Purification of Antibodies, John Wiley & Sons, Hoboken 2009.
19. H. Aranha, BioPharm 2001, 14 (5), 43-54, 90.
20. P.-S. Chang, L.-J. Chen, Y.-C. Wang, Aquaculture 1998, 166 (1-2), 1-17. DOI: 10.1016/S0044-8486(97)00238-X
21. M. de las Mercedes Segura, A. Kamen, A. Garnier, Biotechnol. Adv. 2006, 24 (3), 321-337. DOI: 10.1016/j.biotechadv.2005.12.001
22. J. Zhu, Biotechnol. Adv. 2012, 30 (5), 1158-1170. DOI: 10.1016/j.biotechadv.2011.08.022
23. Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products, European Medicines Agency, London 2006. www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003798.pdf.
24. Q5(R1) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin, International Conference on Harmonisation, Geneva 1999. www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/ Quality/Q5A-R1/Step4/Q5A-R1-Guideline.pdf.
25. Y. Guo, A. Cheng, M. Wang, Y. Zhou, J. Virol. Methods 2009, 161 (1), 1-6. DOI: 10.1016/j.jviromet.2008.12.017
26. R. V. Thurber, et al., Nat. Protocols 2009, 4 (4), 470-483. DOI: 10.1038/nprot.2009.10
27. M. Aboud, M. Wolfson, Y. Hassan, M. Huleihel, Arch. Virol. 1982, 71 (3), 185-195.
28. M. G. Aucoin, J. A. Mena, A. A. Kamen, Curr. Gene Ther. 2010, 10 (3), 174-186.
29. H. Jorio, R. Tran, A. Kamen, Biotechnol. Prog. 2006, 22 (1), 319-325.
30. R. Kutner, S. Puthli, M. Marino, J. Reiser, BMC Biotechnol. 2009, 9 (1), 10.
31. C. Peixoto, et al., J. Biotechnol. 2007, 127 (3), 452-461. DOI: 10.1016/j.jbiotec.2006.08.002
32. S. R. Wickramasinghe, et al., Biotechnol. Bioeng. 2005, 92 (2), 199-208.
33. T. A. Grein, R. Michalsky, M. Vega Lõpez, P. Czermak, J. Virol. Methods 2012, 183, 117-124.
34. C. Charcosset, Biotechnol. Adv. 2006, 24 (5), 482-492.
35. M. I. Hensgen, P. Czermak, J. O. Carlson, S. R. Wickramasinghe, Desalination 2009, 250 (3), 1121-1124.
36. R. Michalsky, A. L. Passarelli, P. H. Pfromm, P. Czermak, Desalination 2009, 250 (3), 1125-1127. DOI: 10.1016/j.desal.2009.09.123
37. R. Michalsky, A. L. Passarelli, P. H. Pfromm, P. Czermak, Desalination 2009, 245 (1-3), 694-700. DOI: 10.1016/j.desal.2009.02.039
38. D. Nehring, et al., Desalination 2009, 245 (1-3), 614-620. DOI: 10.1016/j.desal.2009.02.027
39. H. M. Huotari, G. Trägårdh, I. H. Huisman, Chem. Eng. Res. Des. 1999, 77 (5), 461-468.
40. H. Lutz, et al., Biotechnol. Prog. 2010, 27 (1), 121-128. DOI: 10.1002/btpr.500
41. Viresolve NFP Filter, Millipore, Billerica, MA 2007. www.millipore.com/ publications.nsf/a73664f9f981af8c852569b9005b4eee/ 9078b8eecdb57dcf852573af0078aa4f/$FILE/DS2174EN00.pdf (December 11, 2012).
42. S. R. Wickramasinghe, et al., J. Membr. Sci. 2010, 365 (1-2), 160-169.
43. T. Hongo-Hirasaki, K. Yamaguchi, K. Yanagida, K. Okuyama, J. Membr. Sci. 2006, 278 (1-2), 3-9. DOI: 10.1016/j.memsci.2005.10.057
44. J. Bryce, C. Boschi-Pinto, K. Shibuya, R. E. Black, Lancet 2005, 365 (9465), 1147-1152. DOI: 10.1016/S0140-6736(05)71877-8
45. B. A. Cunha, M. Corbett, N. Mickail, Heart Lung 2011, 40 (1), 76-80. DOI: 10.1016/j.hrtlng.2010.05.060
46. S. A. Baylis, et al., Vaccine 2010, 29 (4), 690-697. DOI: 10.1016/j.vaccine.2010.11.028
47. A. Kerr, R. Nims, PDA J. Pharm. Sci. Technol. 2010, 64 (5), 481-485.
48. A. A. Shukla, et al., J. Chromatogr. B 2007, 848 (1), 28-39. DOI: 10.1016/j.jchromb.2006.09.026
49. A. Roldão, R. Oliveira, M. J. T. Carrondo, P. M. Alves, J. Virol. Methods 2009, 159 (1), 69-80. DOI: 10.1016/j.jviromet.2009.03.007
50. R. Michalsky, et al., J. Virol. Methods 2008, 153 (2), 90-96. DOI: 10.1016/j.jviromet.2008.07.030
51. M. Tsujikawa, et al., J. Virol. Methods 2011, 178 (1-2), 39-43. DOI: 10.1016/j.jviromet.2011.08.009
52. B. F. Marques, D. J. Roush, K. E. Göklen, Biotechnol. Prog. 2009, 25 (2), 483-491. DOI: 10.1002/btpr.177
53. Note for Guidance on virus validation studies: The Design, contribution and interpretation of studies validating the inactivation and removal of viruses, CPMP/BWP/268/96, European Agency for the Evaluation of Medicinal Products, London 1996. www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003684.pdf.
54. C. Charcosset, Membrane Processes in Biotechnologies and Pharmaceutics, 1st ed., Elsevier, Amsterdam 2012.
55. D. H. Kingsley, H. Chen, Int. J. Food Microbiol. 2009, 130 (1), 61-64.
56. T. A. Grein, R. Michalsky, M. Vega Lopez, P. Czermak, J. Virol. Methods 2012, 183, 117-124. DOI: 10.1016/j.jviromet.2012.03.031
57. H. Jorio, et al., J. Virol. Methods 2006, 134 (1-2), 8-14. DOI: 10.1016/j.jviromet.2005.11.009
58. E. V. L. Grgacic, D. A. Anderson, Methods 2006, 40 (1), 60-65. DOI: 10.1016/j.ymeth.2006.07.018
59. M. S. Weinberg, R. J. Samulski, T. J. McCown, Neuropharmacology 2013, 69, 82-88. DOI: 10.1016/j.neuropharm.2012.03.004
60. C. Y. Liang, et al., Arch. Virol. 2003, 149 (1), 51-60. DOI: 10.1007/s00705-003-0197-3
61. T. Vicente, C. Peixoto, M. J. Carrondo, P. M. Alves, Gene Ther. 2009, 16 (6), 766-775.
62. Cervarix® product information: Human papillomavirus vaccine types 16 and 18 (recombinant, as04 adjuvanted), GlaxoSmithKline-Biologicals, Rixensart 2007. www.gsk.com.au/resources.ashx/vaccineproductschilddataproinfo/405/ FileName/6ABEBB12B9D389EC6C229A42F28B0DFB/Cervarix-clean.pdf.
63. G. Bolton, et al., Biotechnol. Appl. Biochem. 2005, 42 (2), 133-142. DOI: 10.1042/BA20050056
64. R. van Reis, A. Zydney, J. Membr. Sci. 2007, 297 (1-2), 16-50. DOI: 10.1016/j.memsci.2007.02.045
65. P. Czermak, et al., Desalination 2008, 224 (1-3), 23-27. DOI: 10.1016/j.desal.2007.04.074
66. Z. H. Syedain, D. M. Bohonak, A. L. Zydney, Biotechnol. Prog. 2006, 22 (4), 1163-1169. DOI: 10.1021/bp050350v
67. X. Zeng, E. Ruckenstein, Biotechnol. Prog. 1999, 15 (6), 1003-1019. DOI: 10.1021/bp990120e
68. Y.-L. Su, W. Cheng, C. Li, Z. Jiang, J. Membr. Sci. 2009, 329 (1-2), 246-252. DOI: 10.1016/j.memsci.2009.01.002
69. S. Kroll, et al., J. Eur. Ceram. Soc. 2012, 32 (16), 4111-4120. DOI: 10.1016/j.jeurceramsoc.2012.07.026
70. H. K. Oh, et al., Desalination 2007, 202 (1-3), 191-198. DOI: 10.1016/j.desal.2005.12.054
71. I. Gutiérrez-Aguirre, et al., J. Chromatogr. A 2011, 1218 (17), 2368-2373. DOI: 10.1016/j.chroma.2010.10.048
72. T. Urase, K. Yamamoto, S. Ohgaki, J. Membr. Sci. 1996, 115 (1), 21-29. DOI: 10.1016/0376-7388(95)00269-3
73. B. Hofs, et al., Sep. Purifi. Technol. 2011, 79 (3), 365-374. DOI: 10.1016/j.seppur.2011.03.025
74. R. Eibl, S. Kaiser, R. Lombriser, D. Eibl, Appl. Microbiol. Biotechnol. 2010, 86 (1), 41-49. DOI: 10.1007/s00253-009-2422-9
75. D. Nehring, R. Gonzalez, R. Pörtner, P. Czermak, J. Membr. Sci. 2004, 237 (1-2), 25-38. DOI: 10.1016/j.memsci.2004.02.027
76. M. Ebrahimi, R. Hackel, G. Catapano, P. Czermak, Desalination 2006, 200 (1-3), 496-497. DOI: 10.1016/j.desal.2006.03.409
77. P. Czermak, M. Ebrahimi, G. Catapano, Int. J. Artif. Organs 2005, 28 (7), 694-700.
78. R. Ghosh, J. Chromatogr. A 2002, 952 (1-2), 13-27. DOI: 10.1016/S0021-9673(02)00057-2
79. R. Specht, et al., Biotechnol. Bioeng. 2004, 88 (4), 465-473. DOI: 10.1002/bit.20270
80. R. Kutner, S. Puthli, M. Marino, J. Reiser, BMC Biotechnol. 2009, 9 (1). DOI: 10.1186/1472-6750-9-10
81. B. Anliker, S. Longhurst, C. J. Buchholz, Bundesgesundheitsbl. 2010, 53 (1), 52-57.
82. S. R. Wickramasinghe, et al., Biotechnol. Bioeng. 2005, 92 (2), 199-208. DOI: 10.1002/bit.20599
83. D. L. Grzenia, et al., Biotechnol. Prog. 2006, 22 (5), 1346-1353. DOI: 10.1021/bp060077c
84. A. L. Zydney, C.-C. Ho, Desalination 2002, 146 (1-3), 75-81. DOI: 10.1016/S0011-9164(02)00492-7
85. S. Akeprathumchai, et al., Biotechnol. Bioeng. 2004, 88 (7), 880-889. DOI: 10.1002/bit.20312
86. S. R. Wickramasinghe, H. Binbing, J. O. Carlson, S. M. Powers, Biotechnol. Bioeng. 2004, 86 (6), 612-621.
87. H. Jorio, R. Tran, A. Kamen, Biotechnol. Prog. 2006, 22 (1), 319-325.
88. M. W. O. Liew, Y. P. Chuan, A. P. J. Middelberg, Biochem. Eng. J. 2012, 68, 120-128. DOI: 10.1016/j.bej.2012.07.009
89. G.-Y. Chen, et al., Biotechnol. Prog. 2009, 25 (6), 1669-1677. DOI: 10.1002/btpr.253
90. I. Tatárová, R. Fáber, R. Denoyel, M. Polakovic, J. Chromatogr. A 2009, 1216 (6), 941-947. DOI: 10.1016/j.chroma.2008.12.018
91. M. Woo, et al., J. Chromatogr. A 2011, 1218 (32), 5386-5392. DOI: 10.1016/j.chroma.2011.03.068
92. E. Klein, J. Membr. Sci. 2000, 179 (1-2), 1-27. DOI: 10.1016/S0376- 7388(00)00514-7
93. J. Barsoum, BioTechniques 1999, 26 (5), 834-840.
94. D.-S. Lee, B.-M. Kim, D.-W. Seol, Biochem. Biophys. Res. Commun. 2009, 378 (3), 640-644.
95. D. Yu, M. D. McLean, J. C. Hall, R. Ghosh, J. Chromatogr. A 2008, 1187 (1-2), 128-137. DOI: 10.1016/j.chroma.2008.02.016
96. C. Wu, K. Y. Soh, S. Wang, Hum. Gene Ther. 2007, 18 (7), 665-672. DOI: 10.1089/hum.2007.020
97. L. Maranga, et al., Appl. Microbiol. Biotechnol. 2002, 59 (1), 45-50. DOI: 10.1007/s00253-002-0976-x